癌症患者患有较高的疫苗可预防疾病风险。推荐接种疫苗是最具成本效益的措施，可减少传播风险和相关并发症。然而，疫苗接种率不足。肿瘤学家在向患者传达个性化疫苗信息方面发挥着核心作用。我们介绍了意大利癌症学会（AIOM）于2022年进行的一项调查的结果，重点关注肿瘤学家对问题的认识。 这是一项31个项目的匿名在线调查，于2022年9月15日在AIOM网站上发布。此调查的目标是考察意大利肿瘤学家对可预防疾病和主要可用疫苗的认知程度，对推荐疫苗的态度以及COVID-19疫情对他们对可预防疾病接种的习惯的影响。 在2022年9月至2023年1月期间，有114名医学肿瘤学家（占会员的5%）完成了此匿名问卷调查。在初诊时，只有30%的受访者通常对所有患者提出接种计划，41%的受访者在初次访问时通常不讨论接种疫苗，29%的受访者仅向特定类别的患者推荐疫苗。对于56%的受访者来说，患者更加了解疫苗的好处，而36%的受访者则报告称患者担心接受过多的疫苗。 这是意大利肿瘤学家进行的首次调查，旨在更好地了解他们对接种疫苗的认识和态度。调查凸显了肿瘤学家在可预防疾病和疫苗意识方面教育和培训的紧迫问题，以及建立（或实施）多学科合作网络的需要。

Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022, focusing on the perception of the problem by oncologists.An anonymous 31-item online questionnaire was shared on 15 September 2022 on the AIOM website. The objectives of this survey were to examine the perception of Italian oncologists on vaccine-preventable diseases and the main available vaccines, their attitude towards recommending vaccines and the COVID-19 pandemic impact on their habits regarding vaccine-preventable diseases.Between September 2022 and January 2023, 114 medical oncologists (5% of the members) completed the anonymous questionnaire. At the first oncological visit, only 30% of respondents usually propose a vaccination schedule to all their patient, 41% do not usually discuss vaccinations at the first visit and 29% recommend vaccines exclusively to specific categories of patients. For 56% of respondents, patients are more aware of the benefits of vaccines, whereas 36% reported that patients are worried of receiving too many vaccines.This is the first survey conducted among Italian oncologists to better understand the perception and attitudes towards the vaccination. It highlights the urgent issues of educating and training oncologists in vaccine-preventable diseases and vaccine awareness and the need to build (or implement) a network of multidisciplinary collaborations.